Medical Center-wide Limited Submission Opportunity: The V Foundation for Cancer Research
Vanderbilt University Medical Center (VUMC) has been invited to participate in a brand new opportunity – The V Foundation BRCA 1,2 Research Collaborative Grants. The V Foundation, challenged by the BRCA Foundation and the Basser Initiative at the Gray Foundation, is seeking contributions to fund BRCA-related cancer research. The foundation is interested in any cancer type that is associated with inherited BRCA mutations and is seeking a broad range of research questions. For instance, but not preferred, research in areas such as mechanisms of cancer causation, therapy resistance, prevention or gene-environment interactions would be within the scope. We hope this call for application stimulates novel, innovative new areas of research beyond typical categories.
VUMC may one candidate for each of the following two categories:
Convergence Team Award: To support research projects that leverage novel collaborations between biomedical scientists and other researchers that might be brought into the field to work together across disciplines to drive our understanding and treatment of BRCA 1,2 related cancers. Each team must include experts in multiple disciplines to create a research plan and drive BRCA 1/-2 cancer research into new and innovative areas. The research may be basic, translational, clinical, or epidemiological in nature. We encourage collaborations within and between research institutions. If the award is made to a collaborative team across multiple institutions, the grant will be made to the institution that nominated the lead PI and that lead institution will manage any sub-contracts with collaborating institutions. The Convergence Team Award is a $2,100,000 grant, paid in increments of $700,000 for each of three years.
Translational Award: Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than five years. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial. The Translational Award is a three-year grant of $200,000 per year.
All nominated applicants must meet all of the following criteria to be eligible to submit an application:
- Applicant must be employed at a U.S. non-profit research institution (e.g. 501c3, Section 170).
- By the Due Date of the Application, applicants who will lead this research team must have all the following:
- Be scientists who hold a faculty position at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination to lead the Translational Research Team. Applicants must be either U.S. citizens or have a legal permit to work in the USA (either temporary or permanent).
About the Awards:
- A maximum of 10% indirect costs (within the award amount) are supported by these awards.
- Each institution may nominate one Lead PI in each grant category to submit an application on behalf of the team
- NIH salary caps are observed
Anyone interested in being considered as either of VUMC’s nominees must submit the following (in PDF format) to LSO@vanderbilt.edu by 5 p.m. on Friday, May 26.
- Brief (2 page maximum) research plan including summary budget;
- Brief statement of support from department chair/center director;
- A brief CV or NIH Biosketch
Submissions should reference the program name in the subject line of the email.
Once received, all proposals will be forwarded to an internal review committee that will choose the final nominee. The chosen nominee will submit a full proposal to the foundation by the July deadline.
If you have any questions about the foundation or its interests and priorities, please contact Megan Smallwood, program manager in the Office of Research.